Playback speed
10 seconds
ASCO 2019 End-of-study Survival Analysis from the Cleopatra Study Shows Significant Benefit for Pertuzumab Plus Trastuzumab/Docetaxel in HER2-Positive Metastatic Breast Cancer
13,910 views
June 26, 2019
Login to view comments.
Click here to Login